Novartis (NVS): New Study Finds Coartem (Artemether-Lumefantrine) Is The Most Effective Malaria Treatment In Areas Of High Resistance To Conventional Anti-Malarials 
10/19/2005 5:10:53 PM

BASEL, Switzerland, April 26, 2005 (PRIMEZONE) -- A new study published in The Lancet suggests that the combination of artemether and lumefantrine, available from Novartis (NYSE:NVS) under the brand name Coartem(R) , is the most effective available treatment for malaria in children in areas of Africa where resistance to conventional anti-malarial drugs is high. Developed and produced by Novartis and its Chinese partners, Coartem is currently the only fixed-dose artemisinin-based combination therapy pre-qualified by the World Health Organization (WHO) for procurement by United Nations agencies.